Clinical and experimental dermatology
Comment on "Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years": clarifying drug survival metrics and capturing joint outcomes.
Jiuyuan Qin, Jie Deng, Yulin Zou
Published: 202610.1093/ced/llag024
No abstract available for this study.